Why Great Science Isn’t Enough Anymore, And How Building a Double IP™ Changes That

Most new product launches fail within the first 12 months. Not because the science was wrong. Not because the market wasn’t ready. They fail because no one understood them, no one trusted them, and no one felt anything for them. That’s the Innovation Trap, and it’s more common than the industry admits.

B2B ingredient companies are especially exposed. You’ve built the evidence. You have the clinical data, the patents, the manufacturing know-how. And yet customers still see you as interchangeable. Competitors copy your technology faster than you can protect it. And somewhere between the lab and the market, the consumer gets lost entirely. The problem isn’t the science. It never was.

In this article, we break down the five structural challenges holding ingredient companies back, and show how building the Double IP by combining scientific IP with a strong brand position creates differentiation that no fast-follower can replicate.

Challenge #1: The Commodity Trap

When you compete on specifications, clinical dosing, and price, you make yourself interchangeable. “We have great science, but customers see us as a commodity” is something we hear constantly. The science is differentiated. The positioning isn’t. That’s not a product problem, it’s a brand problem.

Challenge #2: The Differentiation Gap

Most ingredient companies default to explaining what the ingredient is rather than why it matters. The result is positioning that sounds impressive to scientists and means nothing to buyers or consumers. Features without meaning don’t create preference. They create confusion, and confusion defaults to price comparison.

Challenge #3: The Fast-Follower Threat

Innovation timelines are compressing. A novel ingredient, a proprietary extraction method, a new clinical application, these can be replicated or approximated faster than most companies expect. Patents offer temporary protection. But a well-built brand position creates a moat that competitors cannot copy, even if they can copy the technology.

Challenge #4: The Innovation Disconnect

R&D, marketing, sales, and management often operate in silos. Technology gets developed first; consumer relevance is figured out later, if at all. This creates what we call “technology looking for a market.” The better starting question is: what does this technology mean in people’s lives? Innovation that starts from consumer insight lands very differently from innovation that starts in the lab and then searches for a use case.

Challenge #5: The B2B to B2B2C Transition

An increasing number of ingredient companies are realizing that selling on science alone is no longer viable, because their customers need more than science. They need consumer-friendly storytelling and claims, and demand creation. They need partners, not suppliers. Making that shift requires a different kind of thinking: not just what you sell, but what you stand for.

At HMT, we’ve developed a framework called Double IP™: Intellectual Property plus Intellectual Positioning. The idea is straightforward: competitive advantage comes from combining two types of intellectual capital, not one.

IP #1 — The Science (the What): Patents, science and clinical evidence, manufacturing know-how, unique technology. This is your credibility. It opens doors.
IP #2 — The Brand (the Why): Positioning, purpose, narrative, the emotional territory you own in customers’ and consumers’ minds. This is your belief. It keeps you in the room.

Science creates credibility. Brand creates connection. Together, they create differentiation that can’t be easily copied, and that remains valuable even when patents expire. Because customers buy on evidence, but they choose brands that stand for something.